Edaravone: a new treatment for ALS on the horizon?

[...]the study duration was short, comprising 24 weeks in total, preceded by a 12-week observation period. [...]while it is biologically plausible that sub-cohorts of patients might respond differentially to targeted therapies, how to select such patients remains a conundrum, as at present there are...

Full description

Saved in:
Bibliographic Details
Published in:Lancet neurology 2017-07, Vol.16 (7), p.490-491
Main Authors: Hardiman, Orla, van den Berg, Leonard H
Format: Article
Language:English
Subjects:
Amyotrophic lateral sclerosis
Clinical trials
Free radicals
Intravenous administration
Neurodegeneration
Neurology
Oxidative stress
Patients
R&D
Research & development
Rodents
Side effects
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]the study duration was short, comprising 24 weeks in total, preceded by a 12-week observation period. [...]while it is biologically plausible that sub-cohorts of patients might respond differentially to targeted therapies, how to select such patients remains a conundrum, as at present there are no reliable markers of pathobiology. [...]although the side-effect profile does not suggest toxicity, the treatment regimen of intravenous infusions for 10-14 days each month is inconvenient and potentially costly, and the longer term efficacy of the drug and patient adherence to the intravenous treatment has not been established.
ISSN:1474-4422
1474-4465
DOI:10.1016/S1474-4422(17)30163-1